Article
Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics.
Neuro-oncology - 5 Jan 2023
Yeo Kee Kiat, Alexandrescu Sanda, Cotter Jennifer A, Vogelzang Jayne, Bhave Varun, Li Marilyn M, Ji Jianling, Benhamida Jamal K, Rosenblum Marc K, Bale Tejus A, Bouvier Nancy, Kaneva Kristiyana, Rosenberg Tom, Lim-Fat Mary Jane, Ghosh Hia, Martinez Migdalia, Aguilera Dolly, Smith Amy, Goldman Stewart, Diamond Eli L, Gavrilovic Igor, MacDonald Tobey J, Wood Matthew D, Nazemi Kellie J, Truong AiLien, Cluster Andrew, Ligon Keith L, Cole Kristina, Bi Wenya Linda, Margol Ashley S, Karajannis Matthias A, Wright Karen D
Abstract excerpt
BACKGROUND: The incidence and biology of IDH1/2 mutations in pediatric gliomas are unclear. Notably, current treatment approaches by pediatric and adult providers vary significantly. We describe the frequency and clinical outcomes of IDH1/2-mutant gliomas in pediatrics. METHODS: We performed a multi-institutional analysis of the frequency of pediatric IDH1/2-mutant gliomas, identified by next-generation...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.